Trexquant Investment LP Immunovant, Inc. Transaction History

Trexquant Investment LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$30.27 - $43.79 $1.76 Million - $2.55 Million	58,218 New	58,218 $1.88 Million
Q3 2023 Nov 13, 2023	BUY	$18.55 - $39.96 $1.44 Million - $3.11 Million	77,806 New	77,806 $2.99 Million
Q1 2023 May 15, 2023	SELL	$15.27 - $19.72 $659,786 - $852,061	-43,208 Reduced 55.83%	34,184 $530,000
Q4 2022 Feb 13, 2023	BUY	$6.59 - $17.75 $510,013 - $1.37 Million	77,392 New	77,392 $1.37 Million
Q4 2021 Feb 14, 2022	SELL	$7.33 - $9.32 $133,391 - $169,605	-18,198 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$7.01 - $11.37 $127,567 - $206,911	18,198 New	18,198 $158,000

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.